OMERS ADMINISTRATION Corp purchased a new position in Clorox Company (The) in the 2nd quarter worth approximately $2,184,000. Its stake was valued at $379,505,000 an increase of $101,300,000 according to the filing.
Several other hedge funds also recently bought and sold shares of the company. Moreover, Oppenheimer Asset Management Incorporated has 0.09% invested in Clorox Co (NYSE:CLX). In the last 90 days, insiders have sold 41,293 shares of company stock worth $5,560,303.
When talking about institutional holdings, looking at a public company's current active positions is a good way of figuring out how institutional investors think of the stock's value. Valley National Advisers Inc. now owns 865 shares of the company's stock worth $115,000 after acquiring an additional 5 shares during the last quarter.
Market capitalization of 17.43B shares for the company helps traders interpret the size of The Clorox Company, acting as the basic determinant for numerous important characteristics that affects an investment decision. Ameriprise Financial Inc. increased its position in shares of Clorox Company (The) by 24.6% in the 2nd quarter. Outstanding shares denotes a company's stock now held by all its shareholders, comprising share blocks apprehended by institutional investors and limited shares owned by the officers and insiders of the organization. The stock plunged -0.9 percent over the past quarter, while surged 3.34 percent over the past six months.
Within those holders, 337 of them increased their positions - representing 5,848,002 shares of The Clorox Company (CLX).
It can be helpful for any investor to check out what portion of a company's total shares outstanding are now owned by institutional investors.
CLX has been the topic of a number of research reports. Morgan Stanley has "Equal-Weight" rating and $128 target.
Among 15 analysts covering The Clorox Company (NYSE:CLX), 3 have Buy rating, 2 Sell and 10 Hold.
These firms have modified their investment in CLX. BMO Capital Markets restated an "outperform" rating on shares of Clorox Company (The) in a research report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company's stock. The stock has an average rating of "Hold" and an average target price of $126.09. Earnings per share (EPS) shows a trader what portion of a company's profit is allocated to each outstanding share of common stock. The stock had a trading volume of 718,800 shares, compared to its average volume of 815,927.
The Clorox Company (CLX)'s distance from 200 day simple moving average is 1.19 percent, its distance from 50 day simple moving average is 2.97 percent, while its distance from 20 day simple moving average is 4.76 percent. Clorox Co. has a 12-month low of $113.78 and a 12-month high of $140.47. About shares traded. Clorox Co (NYSE:CLX) has risen 1.68% since November 12, 2016 and is uptrending. The company reported $1.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.41 by $0.05.
The company also recently announced a quarterly dividend, which was paid on Monday, November 13th. With short interest at 6,765,092 and short average daily volume at 1,093,574, the short-interest ratio is 6.0 and the percentage of shorted shares is 0.05% as of October 31. The stock increased 3.46% or $2.1 on November 10, reaching $62.85. The ex-dividend date of this dividend is Tuesday, October 24th. Clorox Company (The)'s dividend payout ratio is presently 61.88%. The stock was sold at an average price of $131.14, for a total value of $673,535.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
In other news, EVP James E. Foster sold 9,861 shares of the business's stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $131.69, for a total transaction of $5,120,370.58. Following the completion of the sale, the executive vice president now directly owns 22,069 shares of the company's stock, valued at approximately $3,056,777.19. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company's stock.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of USA and global copyright and trademark law. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors.